Silence Therapeutics Share Price (SLN)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Silence Ther.	LSE:SLN	London	Ordinary Share	GB00B9GTXM62	ORD 5P

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	+1.50p	+0.61%	245.50p	242.00p	249.00p	254.75p	244.75p	254.75p	31,897	16:35:26

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	0.8	-10.4	-12.1	-	171.83

Related Shares
GlaxoSmithKline (GSK), AstraZeneca (AZN), Valirx (VAL), Port Erin (PEBI)

Silence Therapeutics (SLN) Latest News

Silence Therapeutics News

Date	Time	Source	Headline
19/10/2017	17:50	UKREG	Silence Therapeutics PLC Holding(s) in Company
18/10/2017	14:31	UKREG	Silence Therapeutics PLC Holding(s) in Company
18/10/2017	08:12	ALNC	Silence Therapeutics Granted Two Patents For US Technology
18/10/2017	07:14	ALNCF	Alliance News Flash Headline
18/10/2017	07:00	UKREG	Silence Therapeutics PLC Further US patents granted
17/10/2017	15:32	ALNC	Silence Therapeutics Delivers Claim Against Alnylam In UK High Court
17/10/2017	15:08	UKREG	Silence Therapeutics PLC Serving of claim in the UK High Court
16/10/2017	09:56	ALNC	Silence Therapeutics Appoints Dimension Therapeutics Chief As Chairman
16/10/2017	07:00	UKREG	Silence Therapeutics PLC Appointment of Non-Executive Chair
11/10/2017	09:17	ALNC	Silence Therapeutics Granted US Patent For RNA Treatments

More Silence Therapeutics News

Silence Therapeutics Takeover Rumours

Silence Therapeutics (SLN) Share Charts

1 Year Silence Therapeutics Chart

1 Month Silence Therapeutics Chart

Intraday Silence Therapeutics Chart

Silence Therapeutics (SLN) Discussions and Chat

Silence Therapeutics Forums and Chat

Date	Time	Title	Posts
20/10/2017	16:12	Silence Therapeutics (the old SR Pharma)	47,485
06/10/2016	09:04	Gower Productions Presents ....."PREDICTA BID"	52
05/10/2016	20:29	port	-
29/5/2013	10:32	Silence Therapeutics - news and views	1,412
15/2/2013	08:57	SLN - I see no ships, but I do see 10p looming, ahoy!	368

Add a New Thread

Silence Therapeutics (SLN) Most Recent Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type
2017-10-23 15:25:57	247.50	5,730	14,181.75	O
2017-10-23 13:54:39	242.00	5,000	12,100.00	OK
2017-10-23 12:54:07	247.00	2,386	5,893.42	O
2017-10-23 12:41:23	242.00	1,000	2,420.00	O
2017-10-23 12:27:46	247.00	2,153	5,317.91	O

View all Silence Therapeutics trades in real-time

Silence Therapeutics (SLN) Top Chat Posts

Date	Subject
23/10/2017 09:20	Silence Therapeutics Daily Update: Silence Ther. is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SLN. The last closing price for Silence Therapeutics was 244p. Silence Ther. has a 4 week average price of 185p and a 12 week average price of 125p. The 1 year high share price is 254.75p while the 1 year low share price is currently 72.75p. There are currently 69,991,624 shares in issue and the average daily traded volume is 381,359 shares. The market capitalisation of Silence Ther. is £171,829,436.92. Read Full Thread Reply
28/9/2017 08:23	rogen83: Arrowhead stake now worth £20m or 30p of SLNs share price Good work Ali Read Full Thread Follow Reply
07/9/2017 14:36	1gw: It has at least put the brakes on the share price. Who knows - if there's any truth to the suggestions that Alnylam might look to settle the patent dispute by taking over Silence then now might be a good time to strike. Certainly it seemed to me from the Alnylam call that Alnylam see the Fitusiran death as tragic but by no means an end to their hopes for the drug. Read Full Thread Follow Reply
29/8/2017 09:55	1gw: Anybody any thoughts as to why this rise doesn't seem to have caught the attention and imagination of the day trader crowd? Isn't biotech almost as good as oil/minerals for generating hype, excitement and exaggerated share price moves? Read Full Thread Follow Reply
24/8/2017 15:24	1gw: I can't help feeling there's an element of SLN investors looking at the ARWR price trajectory and thinking something's happening - and ARWR investors looking at the SLN price trajectory and thinking the same. Hopefully there's some substance behind both moves rather than mutually reinforcing illusions... Read Full Thread Follow Reply
21/8/2017 16:19	1gw: I am surprised we haven't had a rush of short-term players to the bulletin boards, given the share price chart. All the better for the future, perhaps, if the share price has done what it has done without much input from the bulletin boards or twitter. Read Full Thread Follow Reply
04/5/2017 16:00	1gw: ARWR is up around 20% this afternoon - not enough to take me into profit on my holding, but makes the loss look a little less severe. They beat on revenue and earnings, thanks (I think) to the Amgen up-front payments, and also announced an analyst R&D day for September to explain what they're doing. They described the Amgen partnership as working well and said in response to a question that they were interested in similar partnerships with other companies and are optimistic that they can enter into additional strategic partnerships. No obvious follow-through to the SLN share price yet, but perhaps ARWR's spike (on heavy volume) will draw some attention to other companies in the sector. Read Full Thread Follow Reply
03/5/2017 14:17	1gw: Well let's hope the ARWR call this evening will be a material event! It's a good point on cash vs market cap/EV. According to the preliminaries, at 31st December they held: £39.0m cash & equivalents £4.4m available-for-sale financial assets (mainly ARWR shares) So £43.4m between the two categories. With about 70m shares in issue that's equivalent to about 62p in cash/equivalents and financial assets. Since year-end they've converted some of the cash into more ARWR shares and they will have burnt through some more cash in running the business. But even so, with a share price in the 70's that's not a lot for the ongoing business, IP, R&D and pipeline. Which is hard to reconcile with Ali's upbeat comments on valuation of RNA therapeutics, for example, in the RNS on the ARWR purchase: "We believe that the recent technological advancements in RNA therapeutics have been underestimated and undervalued. We are confident that the recent market approval of medicines in our field are the beginning of the emergence of an important new class of therapeutics. " So I've bought a third tranche this afternoon - registering as a buy this time. Read Full Thread Follow Reply
03/5/2017 12:54	1gw: Thanks calumross. Thank goodness for the summary slide at the end! Rather alarming share price behaviour today, ahead of ARWR results. Read Full Thread Follow Reply
08/2/2017 14:54	partner: New game to play , watch the arrowhead share price !!. we appear to be in profit already (subject to currency fluctuations). Read Full Thread Follow Reply
12/1/2017 16:13	callumross: "Success in business can often hinge on opportunities taken (or indeed spurned). Yes, you require a good product, or stellar technology and, of course, decent management. But sometimes company-defining moments come down to happenstance and then having the lead-lined stomach to take the plunge. Silence Therapeutics (LON:SLN) has done just that – taken the plunge - with its US$9.6mln acquisition of an 8.4% stake in Arrowhead Pharmaceuticals (NASDAQ:ARWR). Whether it proves to be a pivotal investment only time will tell. At the very least it looks like a well-timed transaction. Less than six months ago, when Arrowhead was valued at just shy of US$730mln, buying a shareholding of this scale was inconceivable (not mention too expensive). Then fate and poor luck intervened (for Arrowhead at least). In November it cancelled three clinical programmes for drugs designed to tackle liver disease, which caused the stock to tumble to a low of US$1.20 from that August high-point of US$8.22. Silence will have been looking on with interest – not least because the two companies are in the same area of research; they are pioneers in RNA interference (RNAi). This is the cellular process of silencing unwanted or harmful genes. The two companies also use similar delivery mechanisms – GalNAc liver technology - so there ought to be areas where the pair can collaborate. The investment starts the ball rolling in this regard – it is a conversation opener. “Any number of scenarios are possible from mergers, takeovers, cross-collaboration, licensing and at default level maybe nothing,” said Silence’s chief executive Ali Mortazavi. “We have taken a worst case that we are left we with a passive investment.” The UK firm is not alone in having taken a view on Arrowhead and backed that hunch with cold hard cash. The giant Amgen handed over an initial US$56.5mln in September to buy into RNAi therapies being developed to tackle cardiovascular disease as part of a deal worth US$617mln in staged payments. It is worth noting the equity investment at US$7.16 a share provided support for a US$500mln valuation of Arrowhead. Amgen’s interest lies with the firm’s GalNAc technology, which is unaffected by November’s decision. In fact, analysts say the platform has significant untapped potential. If the market has spotted the value still inherent in Arrowhead it has been slow to react. Silence has been far quicker to cotton on. “We are in the field and so are much more knowledgeable about what’s happening,” said Mortazavi. Technologies such as Silence’s and Arrowhead’s are undergoing clinical and preclinical assessment yet the market has assigned both discount valuations. Yet the CRISPR gene editing technology, still very much in its infancy, is receiving billions of dollars of investment cash from big pharma, while listed companies are valued between $500mln and $1bn. This is frustrating for those operating in RNAi, though it is also helped create the “extraordinary circumstances” that allowed Silence to make its move. “A lot of different stars aligned at the same time and Arrowhead fell right back into our zone,” said Mortazavi. “There wasn’t [just] one single reason we did this. At its best this could be a very, very important moment in RNA interference and the ability to actually be able to capture something. “These opportunities don’t come around very often and they may be defining moments.” One should remember Silence is first and foremost a drug development company, not an investment vehicle. “We are going down the development path ourselves. You must not forget this,” said Mortazavi. Indeed, the company continues to use its own IP and know-how to progress its liver-targeted preclinical pipeline. In addition, it is expecting pivotal clinical results from its out-licensed phase III and phase II programmes in mid-2018. The share price, up 4%, suggests the market likes the Arrowhead deal. Equally, investors don’t seem to be getting too carried away. And neither is boss Mortazavi: “We are in a place where any number of things can happen, including nothing.” Read Full Thread Follow Reply

Silence Therapeutics share price data is direct from the London Stock Exchange

Your Recent History

LSE

GKP

Gulf Keyst..

LSE

QPP

Quindell

FTSE

UKX

FTSE 100

LSE

IOF

Iofina

GBPUSD

UK Sterlin..

Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P:30 V: D:20171024 05:45:35